<?xml version="1.0" encoding="UTF-8"?>
<p id="para1660">The first Pakistani national survey
 <xref rid="bib45" ref-type="bibr">
  <sup>45</sup>
 </xref> done in 2008 reported that the overall prevalence of HCV was 4·8% and of HBV was 2·5% for that year, with an estimated 13 million people having co-infections. Reusing syringes for therapeutic injections, receipt of contaminated blood or blood products, reuse of razors by barbers, and medical exposure to contaminated sharps were the major risk factors (
 <xref rid="sec1" ref-type="sec">appendix p 2</xref>).
 <xref rid="bib45" ref-type="bibr">45</xref>, 
 <xref rid="bib46" ref-type="bibr">46</xref> The prevalence of HCV in Pakistan is projected to increase by approximately 60% over the next 15 years, which is equivalent to 1 million new cases annually, representing 10% of the global HCV burden by 2030.
 <xref rid="bib42" ref-type="bibr">
  <sup>42</sup>
 </xref> It has been estimated that 510 000 HCV cases treated annually, mass screening, effective awareness campaigns, and availability of sterile equipment would significantly reduce burden of HCV and avert 220 000 liver-related deaths and 116 000 new cases of liver cancer cases in Pakistan in the next 15 years.
 <xref rid="bib42" ref-type="bibr">
  <sup>42</sup>
 </xref>
</p>
